Advertisement

European Journal of Pediatrics

, Volume 150, Issue 3, pp 179–182 | Cite as

The changes of interleukin-2, tumour necrotic factor and gamma-interferon production among patients with Kawasaki disease

  • C. -Y. Lin
  • C. -C. Lin
  • B. Hwang
  • B. N. Chiang
Infectious Diseases

Abstract

Included in this study were 43 cases of mucocutaneous lymph node syndrome (MCLS or Kawasaki disease) treated solely with aspirin. Of these, 19 developed coronary aneurysm. Mononuclear cells (MNC) of these MCLS patients were collected weekly and stimulated either with phytohaemagglutinin (PHA) or PHA plus phorbol myristic acetate. The production of interleukin-2 (IL-2), tumour necrotic factor (TNF) and gamma-interferon (IFN-r) was determined. In addition, IL-2, TNF, IFN-r from serial collections of serum samples of these patients were also measured. The results show that serum IL-2 and TNF were detected in the 1st week, reached maximal plateau in the 2nd and 3rd week and decreased 1 month later. The production of IL-2, TNF and IFN-r from MCLS patients' MNC increased from the 1st to the 3rd week, persisted at a high level for 1 month and then decreased. During the 2nd and 3rd weeks, there were significantly higher serum IL-2 levels and IL-2 production in patients with than in patients without coronary lesions. These observations suggest that the serum IL-2 level and IL-2 production during the 2nd week may serve as a predictive parameter for coronary aneurysm formation. It also suggests that the production of TNF, IL-2 and IFN-r from MNC may contribute to the development of vascular injury in acute MCLS.

Key words

Mucotaneous lymph node syndrome Interleukin-2 Tumour necrotic factor Gamma-interferon 

Abbreviations

IFN-r

gamma-interferon

IL-1

interleukin-1

IL-2

interleukin-2

MCLS

mucocutaneous lymph node syndrom

MNC

mononuclear cells

PHA

phytohaemagglutinin

PMA

phorbol myristic acetate

TNF

tumour necrotic factor

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beuther B, Cerami A (1986) Cachectin and tumor necrotic factor as two sides of the same biological coin. Nature 320:584–588PubMedGoogle Scholar
  2. 2.
    Fujiwara H, Hamashima Y (1978) Pathology of the heart in kawasaki disease. Pediatrics 61:100–107PubMedGoogle Scholar
  3. 3.
    Japan Kawasaki Disease Research Committee (1984) Diagnostic guideline of Kawasaki disease, rev edn 4. Tokyo, Japan, Kawasaki Disease Research CommitteeGoogle Scholar
  4. 4.
    Kato H, Inoue O, Akagi T (1988) Kawasaki disease: cardiac problems and management. Pediatrics 9:209–217PubMedGoogle Scholar
  5. 5.
    Kawasaki T (1969) Mucocutaneous lymph node syndromeclinical observation of 50 cases. Jpn J Allergol 16:178–222Google Scholar
  6. 6.
    Leung DYM, Siegel L, Grady S, Krensky A, Meade R, Reinherz EL, Geha RS (1982) Immunoregulatory abnormalities in mucocutaneous lymph node syndrome. Clin Immunol Immunopathol 23:100–112PubMedGoogle Scholar
  7. 7.
    Leung DYM, Chu ET, Wood N, Grady S, Meade R, Geha RS (1983) Immunoregulatory T cell abnormalities in mucocutaneous lymph node syndrome. J Immunol 130:2002–2004PubMedGoogle Scholar
  8. 8.
    Leung DYM, Geha RS, Newburger JW, Burns JC, Fiers W, Lapierre LA, Pober JS (1986) Two monkines, interleukin-1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during kawasaki syndrome. J Exp Med 164:1958–1972PubMedGoogle Scholar
  9. 9.
    Lin CY, Hwang B (1987) Serial immunologic studies in patients with mucocutaneous lymph node syndrome (Kawasaki disease). Ann Allergy 59:291–297PubMedGoogle Scholar
  10. 10.
    Lin CY, Low TLK (1989) A comparative study on the immunological effects of bovine and porcine thymic extracts: induction of lymphoproliferative response and enhancement of interleukin-2, gamma-interferon and tumor necrotic factor production in vitro on cord blood lymphocytes. Immunopharmacology (in press)Google Scholar
  11. 11.
    Lin CY, Hwang B, Chiang BN (1986) High risk factors in the development of coronary aneurysms in patients with mucocutaneous lymph node syndrome (Kawasaki disease). Acta Cardiologica Sinica 2:253–262Google Scholar
  12. 12.
    Lin CY, Kuo YC, Lin CC, Ou BR (1988) Enhancement of interleukin-2 and r-interferon production in vitro on cord blood lymphocytes and in vivo on primary cellular immunodeficiency patients with thymic extract (Thymostimulin). J Clin Immunol 8:103–107PubMedGoogle Scholar
  13. 13.
    Lin CY, Lin MT, Hsieh YL, Tsao LY (1988) Transient disappearance of immunologic disorders and remission after intercurrent measles infections in children with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 8:207–213PubMedGoogle Scholar
  14. 14.
    Robb RJ (1984) Interleukin 2: the molecule and its function. Immunol Today 5:203–206Google Scholar
  15. 15.
    The Third International Kawasaki Disease Symposium (1988) Tokyo, Japan, 29 Nov-2 Dec. Japan Heart Fundation, Tokyo, pp 21–26Google Scholar
  16. 16.
    Yanagawa H, Kawaski T, Shigematsu I (1987) Nationwide survey on kawaski disease in Japan. Pediatrics 80:58–62PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • C. -Y. Lin
    • 2
  • C. -C. Lin
    • 1
  • B. Hwang
    • 2
  • B. N. Chiang
    • 1
  1. 1.Department of Medical ResearchVeterans General HospitalTaipeiTaiwan Republic of China
  2. 2.Department of PediatricsVeterans General HospitalTaipeiTaiwan Republic of China

Personalised recommendations